Clinical Trial Update: Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating bortezomib for high-risk acute myeloid leukemia in remission; the study was terminated with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Status: TERMINATED | Results posted: 2017-04-04